

Learn how Oncotype DX® AR-V7 Nucleus Detect™ test may help you

AR-V7 Nucleus Detect is a test for patients with metastatic prostate cancer. Metastatic means the cancer has spread from your prostate to other parts of your body.

Your doctor may order this test for you if your cancer is progressing, even though you are receiving treatments like Zytiga® (abiraterone) and Xtandi® (enzalutamide), also called AR-targeted therapies.

AR-targeted therapies help slow the growth of prostate cancer—but they can stop working over time.

What is AR-V7?

Androgen hormones, such as testosterone, activate or “switch on” androgen receptors (AR) in your body, causing tumors to grow. AR-targeted therapies help slow tumor growth by reducing androgens or blocking the receptors.

Sometimes, your cancer may try to outsmart your therapy by changing or altering your receptors—AR-V7 is an example of this. If AR-V7 is found within your tumor cells, AR-targeted therapies will no longer work for you.

This is called having an AR-V7 positive status.

The AR-V7 Nucleus Detect test tells you and your doctor what your AR-V7 status is, which can help you decide what is next in your treatment plan.

Once the Oncotype DX® AR-V7 Nucleus Detect™ test has been ordered for you:

The Patient Access Program helps make sure your test is affordable, available, and accessible.

To learn more about the program and insurance coverage for this test:

- Visit OncotypeIQ.com
- Call **(866) ONCOTYPE (866-662-6897)** or **877-444-9876** for assistance in Spanish

For more information about genomic testing and the AR-V7 Nucleus Detect test, visit OncotypeDXARV7.com.

Oncotype DX AR-V7 Nucleus Detect is a collaboration between Genomic Health and Epic Sciences™.

Genomic Health Inc. is the world’s leading provider of genomic-based diagnostic tests, guiding treatment decisions for more than 800,000 cancer patients worldwide.

Epic Sciences Inc. develops novel diagnostics to improve patient lives by enabling precision medicine with noninvasive tests that profile rare cells in cancer.



AR-V7 Nucleus Detect, Genomic Health, “Making cancer care smarter,” Oncotype DX, and Oncotype IQ are trademarks of Genomic Health, Inc. All other trademarks are the properties of their respective owners. © 2017 Genomic Health, Inc. All rights reserved. GHI60013_1017



FOR PATIENTS WITH
METASTATIC PROSTATE CANCER

Oncotype DX® AR-V7
Nucleus Detect™ test:
**Know when to
consider another
treatment direction**




Why this test was ordered for you

Know for sure what your options are

With the Oncotype DX® AR-V7 Nucleus Detect™ test, you and your doctor can easily determine your AR-V7 status. Based on your results, you and your doctor can then confidently move forward with the treatment that is right for you.

Metastatic castration-resistant prostate cancer (mCRPC)



What your AR-V7 status means

Your AR-V7 status will tell you if AR-targeted therapies will not work for you



If you are AR-V7+

- AR-V7 was found in your tumor cells
- AR-targeted therapies will no longer work for you
- Your doctor may recommend chemotherapy or other therapies



If you are AR-V7-

- AR-V7 was **not** found in your tumor cells
- AR-targeted therapies may still work for you, but they may not
- Ask your doctor about your treatment options—he or she may keep you on your current therapy or recommend a treatment change

Your AR-V7 status can change

Some patients may develop resistance to AR-targeted therapies over time. Drug resistance means that the cancer has changed and the drugs no longer work like they are supposed to. So, even if you know your AR-V7 status now, you may need to be tested in the future to see if your AR-V7 status has changed.

It's simple to determine your AR-V7 status



Get blood drawn



Receive results
Sent to your doctor
in about 7 days



Discuss results



Decide next steps